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REVIEW
Novel CNS drug discovery and development approach: model-based integration to
predict neuro-pharmacokinetics and pharmacodynamics
Elizabeth C. M. de Lange, Willem van den Brink, Yumi Yamamoto, Wilhelmus E. A. de Witte and Yin Cheong Wong
Leiden Academic Center of Drug Research, Translational Pharmacology, Leiden University, Leiden, The Netherlands
ABSTRACT
Introduction: CNS drug development has been hampered by inadequate consideration of CNS pharma-
cokinetic (PK), pharmacodynamics (PD) and disease complexity (reductionist approach). Improvement is
required via integrative model-based approaches.
Areas covered: The authors summarize factors that have played a role in the high attrition rate of CNS
compounds. Recent advances in CNS research and drug discovery are presented, especially with regard
to assessment of relevant neuro-PK parameters. Suggestions for further improvements are also
discussed.
Expert opinion: Understanding time- and condition dependent interrelationships between neuro-PK
and neuro-PD processes is key to predictions in different conditions. As a first screen, it is suggested to
use in silico/in vitro derived molecular properties of candidate compounds and predict concentration-
time profiles of compounds in multiple compartments of the human CNS, using time-course based
physiology-based (PB) PK models. Then, for selected compounds, one can include in vitro drug-target
binding kinetics to predict target occupancy (TO)-time profiles in humans. This will improve neuro-PD
prediction. Furthermore, a pharmaco-omics approach is suggested, providing multilevel and paralleled
data on systems processes from individuals in a systems-wide manner. Thus, clinical trials will be better
informed, using fewer animals, while also, needing fewer individuals and samples per individual for
proof of concept in humans.
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The aim of drug discovery and development is to find com-
pounds able to modify body processes by interaction with a
target that is related to a disease. It typically consists of a
number of phases. These include:
Target identification: aiming to find a molecular target that
is involved in the disease (progression);
Target validation: investigating if the target is ‘druggable’;
Lead discovery: identification of small molecules that mod-
ulate the target, and transformation of the obtained informa-
tion into a high content lead series;
Drug candidate selection: identification of a few promising
compounds, using in silico and preclinical in vitro and in vivo
testing to further understand the compound properties with
regard to its pharmacokinetics (PK), pharmacodynamics (PD,
the therapeutic effects and side effects), mechanisms of
action, and the best dosage and route of administration;
Clinical studies (phase 1–4): investigation of the PK and
safety in human, followed by the analysis of the therapeutic
effects in healthy subjects and in patients and, if not ‘first in
class,’ comparison with similar drugs to obtain a drug that is
‘best in class.’
CNS drug discovery has been hampered by inadequate
understanding or consideration of a number of factors. These
include the complexity of brain anatomy and function; the
neuro-PK with regard to blood–brain barrier (BBB) transport
and intra-brain distribution as well as the measures to study
these processes; adequate biomarkers of CNS drug effects
(neuro-PD), and the complex nature of CNS diseases [1]. Also,
the reductionist view and thereby lack of understanding of the
interaction and interdependencies of all these factors have
contributed to the high attrition rates of CNS drugs. These
factors are discussed below, while recent improvements in
techniques and approaches to understand neuro-PK and PD
will be discussed in the next section.
1.1. The CNS is an organ with complex anatomy,
structure, and function
While in many tissues in the body a drug is relatively free to
exchange between blood and the extracellular space in the
tissues, this is not the case for CNS tissue. The CNS is separated
from the blood by BBB and other barriers that have highly
specialized properties [2], which has a huge impact on the
relationship between plasma PK and neuro-PK. Moreover, the
CNS is far from being a homogenous tissue. It has many
different tissue structures and fluid cavities (ventricles), while
target expression may variate substantially among the differ-
ent locations [3] and, also, the same target may have distinct
functions in different locations. Furthermore, there is fluid
flow. The main fluid is the cerebrospinal fluid (CSF) that is
produced by the choroid plexus cells of the blood–CSF barrier
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(BSCFB). Then there is the brain extracellular fluid (brain ECF)
produced by the BBB, which flows into the direction of the
ventricle (called brain ECF bulk flow). Brain ECF merges with
the CSF, and the CSF is eliminated via the arachnoid villi into
the blood stream. CSF production and elimination rates deter-
mine the CSF turnover rate [4]. Moreover, very recently, it
became apparent that also the CNS contains lymphatic ves-
sels, thus also lymph flow needs to be taken into account [5].
All these processes have an impact on (local) neuro-PK.
Furthermore, CNS functionality is complicated by the networks
of interacting neurotransmission pathways. Neurotransmitter
receptors have been the typical target for many (classical) CNS
drugs, while ‘single target’ pharmacological intervention and/
or the impact of a disease on one target will often influence
another one. Last but not least, neuro-PD is typically not
directly quantifiable and needs to be assessed in an indirect
way, using biomarkers that may be more or less adequate in
reflecting the real CNS effect. This makes neuro-PD difficult to
measure and to predict.
1.2. The inaccessibility of the human brain for sampling
Since the driving force of CNS drug action is the concentra-
tion-time profile of the drug at the target site, it is important
for pharmaceutical companies to have effective and cost-effi-
cient tools to measure and predict human brain target site
exposure before proceeding to more expensive clinical trials.
However, the possibility of direct measurement of human
brain concentrations is highly limited. Since information on
CNS drug distribution in human brain typically cannot be
obtained directly, it must be inferred from in silico, in vitro,
and in vivo preclinical experimental approaches.
1.3. Inadequate knowledge on neuro-PK
Neuro-PK results from transport across the BBB and BSCFB,
intra-brain distribution, and target interaction. The free drug
hypothesis has been around for many years stating that the
unbound drug concentration is available for membrane trans-
port and target interaction. Wang and Welty [6] were the first
to show the importance of using unbound drug concentra-
tions in proper calculations of BBB transport and intra-brain
distribution, and to introduce the term ‘volume of distribution
in brain’ as the extent of drug distribution between brain
unbound concentrations to total amount of the compound
in the brain tissue. However, in CNS drug discovery, the mea-
surement of unbound drug concentrations is typically not
applied, not just because of the lack of quick and easy assay
methods, but also because of a lack of understanding of the
drivers in neuro-PK processes. Instead, total brain drug con-
centrations are used to determine BBB permeability (rate) of a
drug as well as its total brain over total blood concentration
ratio (Kp, brain, logBB; extent). The values of these parameters
were considered as good indicators of brain penetration and
thereby target exposure (the higher the better), often without
proper understanding of the difference between rate and
extent of BBB transport. This has appeared to be misleading
in understanding rate versus extent of BBB transport and intra-
brain distribution. With that, also the link to target exposure
and interaction could not be made appropriately.
1.4. Incomplete information on and understanding of
the complex CNS diseases
CNS diseases are typically multifactorial and complex. They
often have genetic, physiological, neurochemical, degenera-
tive, and inflammatory components, which display variation
within the patient group [7,8]. For example, for Alzheimer’s
disease, Parkinson’s disease, and other neurodegenerative dis-
orders, multiple- and in many cases divergent-disease etiolo-
gies are involved. Moreover, CNS diseases often get diagnosed
in a late stage of the disease, where the chance of curing the
disease is virtually zero, where at best disease progression can
be halted and often symptom suppression is the only possibi-
lity left. Altogether, this makes that defining a CNS disease,
and its state and stage, is very difficult.
1.5. Problems in identification and validation of targets
for (potential) CNS drugs
Target validation aims to determine whether a biological
compound (e.g. receptor, enzyme, DNA/RNA) is directly
involved in the disease of interest, and whether it can be
modified by a drug or other interventions. For example, if a
human disease is the result of a single gene mutation, and
that mutation can be corrected therapeutically, the target is
validated. An example of this is Huntington’s disease, for
which the causative gene huntingtin was identified many
years ago [9]. However, to date, no successful therapeutic
approach has been demonstrated on the basis of that knowl-
edge, indicating that a valid target does not per se guarantee
the development of a drug [10] Moreover, in many cases the
etiology of CNS diseases is multifactorial, making target iden-
tification and validation difficult if not impossible when focus-
ing on single targets. Indeed, satisfactory treatment of the
disease via a single target might be an illusion.
Article highlights
● Factors that govern neuro-PK and CNS target exposure profiles
plasma PK, BBB transport, brain extracellular-intracellular and brain-
intracellular-subcellular distribution, as well as brainECF bulk flow and
CSF turnover. Information on these factors should include unbound
and bound drug concentrations, and integration of these factors is
needed for understanding neuro-PK, as the underlying processes
occur simultaneously and are interdependent.
● Experimental approaches should be such that a distinction can be
made between drug specific and system specific properties. With
such information the recently developed CNS PBPK model can be
further informed, to allow for scaling between drugs and/or scaling
between species to predict CNS target exposure profiles.
● CNS target exposure profiles can be used to predict CNS TO profiles,
by incorporation of drug-target binding kinetics, endogenous ligand-
target binding kinetic and target turnover.
● Typically, multiple biological pathways are involved in a single CNS
disease, and single pathways are associated with multiple diseases.
This indicates the need for a systems approach for identification and
validation of targets for (potential) CNS drugs
This box summarizes key points contained in the article.
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1.6. Reductionist view and fragmented information
Then last, but certainly not least, there has been the tendency to
oversimplify the relevant factors underlying disease and drug
effects. These factors were evaluated in isolation, neglecting the
complex interactions and interrelationships. Parameter values
for a very high number of compounds have been assessed,
often in high-throughput mode in different systems, without
taking into account the context dependency of these values.
Such ‘fragmented’ and ‘stand-alone’ data did not lead to
increased understanding. Apparently, for the CNS, with its com-
plex PK, PD and disease processes, there has not been an easy
way out. To paraphrase Einstein: ‘Everything should be made as
simple as possible, but no simpler.’
2. Current advances in approaches and techniques
For a proper CNS effect, the drug should have the ability to
access the CNS ‘at the right place, at the right time, and at the
right concentration.’ Research advances in chemistry, drug
metabolism, pharmacology, and toxicology have provided
much insight into understanding the pitfalls of the drug dis-
covery and development, and a number of advances in CNS
drug discovery are currently embraced.
2.1. Identification and validation of targets for
(potential) CNS drugs
The ‘omics’ and ‘profiling’ research area clearly indicates that
neurodegenerative diseases and their associated neuropsy-
chiatric comorbidities are multifactorial in origin. Genomics
has provided many molecular targets that provide both
opportunities and challenges in the discovery and develop-
ment of novel medicines for the treatment of human CNS
disorders [11–13]. In addition, more is learned about the biol-
ogy of CNS diseases, and syndromes may be subdivided into
more specific categories that are better understood in terms of
pathophysiology and patho-etiology, also with regard to early
signs of the CNS disease. This is likely to lead to development
of more targeted treatments, being focused on the underlying
causes of the disease as well as its prevention (life-style,
diet, etc.).
In general, the research focus has shifted from single target
toward target networks (systems pharmacology), as networks
include the compensatory factors that impact the neuro-PD
[7,10,11]. These networks are constructed on basis of inte-
grated genomics, proteomics, and metabolomics data, nar-
rowing down the large number of potential genomics-
informed targets into a fewer number of relevant disease-
causing targets [14,15]. Metabolomics has the advantage that
the measured metabolites are accessible from body fluids
such as plasma and urine, which provides opportunities for
biomarker discovery for clinical application. CNS diseases are
often associated with energy substrates, amino acids, neuro-
transmitters, neurochemicals and structural lipids. Typically,
multiple pathways are involved in a single disease, and single
pathways are associated with multiple diseases, underlining
the need for a systems approach in CNS drug develop-
ment [15].
Although not being an example in the CNS area, Cho
et al. [16] suggested a useful approach that is different
from conventional screening systems: the phenotypic
screening in combination with multi-omics-based target
identification and validation (MOTIV). The phenotypic
screening provides information on the effect of small mole-
cule compounds in the cell or at organism level, since small
molecules not only affect a single target but the entire
cellular mechanism within a cell or organism. The MOTIV
approach provides a systematic approach to discover the
target protein of a bioactive small molecule. Then, network
analysis and validations of these candidates result in identi-
fying the biologically relevant target protein and cellular
mechanism. The combination of phenotypic screening and
MOTIV may provide an effective approach to discover new
bioactive small molecule and their target protein and
mechanism of action.
Target identification and validation may be further
informed by pharmacometabolomics, which is a new
approach to identify changes in the metabolome upon drug
action, revealing potentially perturbed biological pathways. A
lipidomics analysis revealed a broad range of lipids changing
upon treatment with the antipsychotics risperidone and olan-
zapine, but not aripiprazole [17]. These changes are associated
with weight gain as a side effect. Furthermore, an analysis of
multiple hormones and biogenic amines after treatment with
the dopamine D2 receptor antagonist remoxipride revealed
diverse response profiles. With integrated PK–PD analyses,
multiple in vivo potencies for these responses were deter-
mined, associated with several biological pathways. These
included the dopamine metabolism, the adrenaline metabo-
lism, the serine–glycine–threonine metabolism, and the sero-
tonin metabolism [18,19].
2.2. Understanding neuro-PK
Drug distribution into and within the brain is governed by
many processes, including plasma PK, plasma protein binding,
passive and active transport across the BBB and BCSFB [2], and
once within the brain, brain ECF bulk flow, diffusion, passive
and active extracellular–intracellular exchange, and CSF turn-
over. In the preclinical setting, there are several in vitro, ex vivo,
and in vivo techniques that provide information on brain
target site exposure. Such information can provide either
direct or indirect information on bound and/or unbound con-
centrations, with or without temporal resolution, with or with-
out spatial resolution, and with or without a clear distinction
between rate and extent of the processes involved. It is of
great importance to understand the mechanisms involved in
uptake into and efflux from the brain, on one hand being
governed by BBB functionality in terms of passive (paracellular
and transcellular) diffusion, facilitated diffusion, active influx,
active efflux, and absorptive or receptor-mediated endocyto-
sis, and, on the other hand, by drug physicochemical proper-
ties and structure. As only the unbound drug is able to pass
through the membranes, it is the unbound concentration
difference between brain and plasma that drives BBB trans-
port. Likewise, it is the unbound concentration difference
between brain ECF and the cellular cytosol that drives extra-
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intracellular transport. Also, for drug–target interaction the
unbound concentration is the driving factor [20].
2.2.1. Neuro-PK measurement
Recently, a number of important improvements have been
made in the understanding of drug distribution into and
within the brain. This has been brought about especially by
new approaches which have been developed, that allow a
relatively rapid and easy assessment of unbound concentra-
tions in brain tissue (brain homogenate dialysis equilibration
and brain slice method) [21,22]. Thus, it is possible to deter-
mine the brain over plasma ratio of unbound concentrations
(extent of brain equilibration; Kpuu,brain), and extra-intracel-
lular unbound concentration ratios (Kpuu, cell). Furthermore,
based on the pH partitioning theory, subcellular distribution
into lysosomes can be simulated. With the new Combinatory
Mapping Approach [23], the relationship between plasma PK
and neuro-PK can be obtained in a more high-throughput
mode, which makes it very useful for drug discovery
(Figure 1). These approaches, however, still the focus on
(assumed) steady-state conditions.
2.2.2. In silico prediction of BBB transport and brain
distribution
In silico approaches to predict BBB permeability in earlier days
were typically based on Kp, brain (logBB) relationships and
found lipophilicity to be the main driver [24]. As discussed
earlier, BBB permeability, which is the rate of BBB transport,
was often confused with the extent of brain distribution,
which confounded the search for good predictors of brain
exposure. Other in silico approaches have focused on quanti-
tative structure–property relationships (QSPR), using the phy-
sicochemical properties of a drug as predictors of the rate and
extent of BBB transport and brain distribution [25–29].
With unbound concentrations taken into account, it was
reported that the main drug property governing the extent of
brain distribution is the number of hydrogen bond acceptors.
Thus, higher lipophilicity is a helpful property for faster rate of
transport across the BBB, while a low number of hydrogen
bond acceptors helps in a larger extent of brain distribution.
Nevertheless, higher lipophilicity may increase nonspecific
binding to brain tissue, while also highly lipophilic compounds
have a tendency to be substrates for efflux transport, such as
by P-glycoprotein, which leads to a net decrease of brain
distribution. Thus, in contrast to earlier guidelines, drugs
aimed for the CNS should not be too lipophilic, and have a
low number of hydrogen bond acceptors for a more extensive
brain distribution of the unbound drug.
It should be noted that in many academic investigations
and CNS drug discovery programs, the focus is still on
(assumed) steady-state conditions. The argument is that with
aiming for a repeated/chronic dosing, a steady-state condition
will be reached, so that only steady-state conditions are rele-
vant to investigate. However, fluctuations in drug levels may
have important consequences for target occupancy (TO), etc.
This will be discussed in the target binding kinetics section
below.
2.2.3. In silico prediction of neuro-PK
A very useful approach to predict neuro-PK is to make use of
physiology-based pharmacokinetic (PBPK) modeling. As in
PBPK modeling, the explicit separation is made between
drug and systems properties, it is a great translational tool.
To date, many more or less complex (semi-)PBPK models have
been published for CNS drug distribution [30–34]. Gaohua
et al. [33] published a human PBPK model with a few physio-
logical CNS compartments. Other (semi-) PBPK models have
been developed using extensive information obtained from
preclinical species, with explicit inclusion of unbound drug
concentrations [31,32]. To that end, the microdialysis techni-
que [35] provided valuable data that were obtained in parallel
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Figure 1. The combinatory mapping approach. (Redrawn from [23] with permission of Springer).
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toward the generic semi-PBPK CNS drug distribution model.
This model has been applied to nine compounds with highly
different physicochemical properties and demonstrated excel-
lent description of the rat data for all these compounds, and
an adequate prediction of human CNS data that were avail-
able for acetaminophen and morphine [34]. Here, it should be
noted that one microdialysis experiment in a single freely
moving animal can provide lots of serial data points, obtained
under the same experimental condition of the animal, and
thereby revealing the interrelationships of neuro-PK processes
[36,37], which in addition is important also for refinement,
reduction, and replacement of animal experiments [38].
Advanced multilevel experiments and mathematical modeling
are needed to reveal interrelationships between processes
that occur in parallel in the body, and to reduce the use of
animals. The ultimate goal is to develop a generic PBPK model
by which prediction of CNS drug distribution can be made
without the need for animal data. Such a model has recently
been developed [39] (Figure 2) and shows good agreement
with the observed in vivo data (Figure 3), and therefore seems
suitable to be used as an ‘in silico’ screening method for
adequate CNS drug distribution of new chemical entities.
2.3. Target binding kinetics
Target binding kinetics and the resulting induction of signal
transduction processes will ultimately lead to a biological
effect. Therefore, in current CNS discovery programs, TO is
often measured, for which equilibrium is often assumed
between free and target-bound drug concentrations [40].
However, this equilibrium is not always reached quickly or
maintained continuously after it has been reached [41–43].
The rate of drug-target equilibration (the binding kinetics) is
determined by the drug-target association rate constant (kon)
and the drug-target dissociation rate constant (koff). Drug-
target binding kinetics not only influences the time course of
TO, but also affects the local drug concentration around the
target for drugs with a high affinity or a high local target
concentration [42,44]. This is important as target concentra-
tions (e.g. receptor density) may differ substantially between
different CNS regions (Figure 4). If target concentrations or
drug target affinities are high enough, the influence of target
binding on drug concentrations can also be observed from
plasma concentrations, as illustrated in Figure 5. Recently,
there have been efforts from both academic and industrial
research communities to advance the in silico and in vitro
assessment of binding kinetics, and the translation of this
knowledge into in vivo settings. One of these efforts is the
Kinetics for Drug Discovery Consortium, a 5-year public–pri-
vate partnership which aimed to define the role of binding
kinetics in drug discovery [46].
For understanding the influence of target binding kinetics
on in vivo drug action, it is therefore important to have



































Figure 2. The structure of the generic CNS PBPK model Structure: Black: Plasma PK model, Red: CNS PBPK model. Parameters: Black: estimated plasma PK
parameters; Blue: system-specific parameters; Green: drug-specific parameters; Purple: combination of system-specific and drug-specific specific parameters.
(Redrawn from [39] with permission of Wiley & Sons).
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compound in plasma and in brain regions where the target
resides. Both ex vivo and in vivo TO of drugs can be evaluated
in experimental animals using both invasive and noninvasive
methods [47]
The ex vivo approach uses tissue slice autoradiography, or
biochemical measures of TO, wherein the fraction of total
target binding sites occupied by the drug is inferred from
the residual binding capacity of a radiotracer added to the
postmortem tissue ex vivo. The in vivo approach, on the other
hand, measures the displacement of the radiotracer from the
target tissue when both the drug and the radiotracer are
administered to the living animal. In the past decade, the
use of non-radiolabeled tracers is increasingly adopted in in
vivo studies, in which the tissue concentration of the adminis-
tered non-radiolabeled tracer is quantified by liquid chroma-
tography-mass spectrometry (LC-MS) instead of radioactivity
counting [48]. The main advantages of this method are that
the parent tracer can be differentiated from its metabolites,
and it allows simultaneous quantification of the tracer displa-
cement (TO) and the neuro-PK [49]. The measurement of TO
D3 + D5 
hypothala
mus
D1 + D2   
corpus 
striatum



































Figure 3. BPPK model prediction (red lines for median and 95% percentiles) and observed data (black dots) obtained in the five color-filled compartments.
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and target site PK can provide valuable insight into the driving
factors for the time course of drug action. However, additional
factors such as target turnover/desensitization, endogenous
ligand binding, and signal transduction can also influence
the time course of drug action and need to be taken into
account [47].
In humans and animals, TO can be evaluated noninvasively
using positron emission tomography (PET) or single-photon
emission computed tomography (SPECT). These imaging tech-
niques are powerful because they provide high temporal and
spatial resolutions. PET radioligands are now available for
more than 40 CNS targets [50]. PET/SPECT is most useful
when no easily measurable clinical PD markers are available,
or when substantial time is required before an indication of
efficacy can be observed clinically. In this respect, PET/SPECT
can be used to demonstrate that the drug candidates reach
their target and bind to their target, as a proof of concept
enabling effective treatment. Moreover, PET/SPECT imaging
can also be used to identify whether a delay between plasma
unbound drug concentrations and CNS effect is caused by
slow target equilibration or by slow transduction processes.
Dose (or plasma concentration)-TO curves can be obtained to
guide the dosing in clinical trials [50–52].
Drug-target interactions are increasingly incorporated in
mechanism-based PK–PD modeling to support drug develop-
ment. These models allow quantitative assessment of the
relation between neuro-PK and TO. As already discussed,
PBPK modeling is particularly useful in translating the
obtained information from animals to humans by using the
available knowledge on species-dependent physiological char-
acteristics such as blood flow and organ volumes [53–55].
Based on the exposure–response relationship in the animal
species and using TO as a translational biomarker, the efficacy
of a drug candidate in humans could be predicted in early
stage development. Systematic implementation of transla-
tional modeling can therefore bolster confidence of success-
fully evaluating proof of mechanism in humans and ultimately
improve the success rate in Phase II, which is currently only
around 10% [56]. Thus, to predict drug effects based on TO,
integration of all determining factors is required, including
drug transport between blood and CNS, CNS fluid flows, target
site PK profile, drug-target binding kinetics, endogenous
ligand-target binding kinetic, and target turnover.
2.4. CNS drug effects
Many times neuro-PK, and/or TO, is studied without measuring
associated (biomarkers of the) drug effects. Actually, it would
be of great added value if neuro-PK and associated PD would
be obtained in a single experimental subject or at least single
experimental context, as rate and extent of body processes are
context dependent (according to the Mastermind Research
Approach [36]). To link (neuro-)PK to the physiologic response,
PK–PD modeling is often applied. Depending on the PK, as
well as the type of response (inhibition or stimulation), differ-
ent PK–PD models can be used. With that, it is possible to
learn more about factors that play a role in target activation
and signal transduction to the ultimate effect or biomarker of
the effect [57–61], interspecies differences in concentration–
effect relationships [62], tolerance and sensitization [63], and
intra- and interindividual variability. Moreover, for studies with
only PK and PD observations but not TO data, a delay between
Figure 5. Compared plasma pharmacokinetics of high affinity compounds (top row) and their low affinity analogues (bottom row). The circles represent observed
plasma concentrations in rats, the lines represent model predictions. (Reprinted from [45] with permission of ASPET).
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the PK and PD is often be explained by a biophase (or effect
compartment) distribution model. However, incorporating
drug-target binding into the model might explain the same
delay and could be more mechanistic [64]. On the other hand,
when solving the shortcomings in knowledge on target site
distribution of drugs, the principles of the operational model
of agonism (receptor theory) will provide the basis for future
developments in drug development by classifying drugs and
predicting their mechanism of action in pharmacology [65–
68]. PK–PD approaches have typically focused on anticipated
drug effects. As drug probably has additional, unknown
effects, quantitative insights in CNS drug effects should better
be obtained for the whole biological system, including the
unknown mechanisms of action [69,70].
2.5. Biomarkers of drug effects and disease
To predict the drug effects in human on the basis of transla-
tional animal and mathematical models, specific expressions
are needed to quantitatively characterize the processes on the
causal path between drug administration and effect. These
include target site distribution, target binding and activation,
transduction, PD interactions, and homeostatic feedback
mechanisms. Ultimately also the effects on and of disease
processes and disease progression have to be considered.
These can be characterized by biomarkers according to the
biomarker classification system [71] (Table 1).
Obtaining combined information on a number of biomar-
ker types (preferable in parallel, within a single biological
system) will allow the development of better models, with
increased accuracy and predictability. The better we will be
able to develop predictive models in preclinical studies, the
more the number of often extremely costly clinical studies can
be reduced. The focus should therefore be on the design of
quantitative in vivo animal studies such that translational
pharmacology approaches can be applied [25,36,37,61,89],
which will be discussed below. In refined animal models, the
biomarkers of the effect that can be measured in both animals
and human will be particularly useful.
Multimodal neuroimaging that combines PET/SPECT with
techniques like magnetic resonance imaging, computed
tomography, and electroencephalography can simultaneously
provide anatomic, functional, biochemical, and metabolic
information alongside TO assessment. These techniques are
increasingly employed in assessing the pathophysiological
changes in different disease states, such as target expression,
release of endogenous ligands that bind the drug target (e.g.
neurotransmitters), neuroinflammation/glial activation, cere-
bral blood flow, and BBB integrity, all of which could alter
the drug PK, TO, and biomarker profiles [50–52].
To obtain insight in the multiple processes in the biological
system, increasing efforts are made to show the utility of a
multi-biomarker approach, both in disease conditions and
upon drug administration [17,90]. With that, the system-wide
pathophysiological and pharmacological influences are
reflected by a multi-biomarker response. To that end, it is
important to connect such data to information on drug dis-
tribution to target sites, target binding kinetics, signal trans-
Table 1. Biomarker classification [71] and approaches to assess quantitative information.
Biomarker Description Approaches References
Type 0 Genotype or phenotype Genotype and phenotype are determinants of the drug response, that influences
target site exposure or response due to variation in the expression of e.g.
enzymes or receptors. High quality gene expression data have significantly
impacted the direction of investigation by allowing for a better molecular
understanding of BBB development, function, and dysfunction. Genome-wide
microarray expression data sets for the BBB have become available. Also
changes in disease conditions have been investigated. Information on protein
expression levels of transporters and receptors can be obtained using
quantitative targeted absolute proteomics, whereas information on enzyme
conversion rates can be identified using quantitative targeted metabolomics.
[72–77]
Type 1 Drug concentrations in general and at the
target site in particular.
Quantitative biomarkers that represent the target site distribution of drugs and
metabolites for compounds that act in the CNS are difficult to obtain in man,
but are readily available in vivo in animals.
[3,6,31,32,34,75]
Type 2 Degree of target occupancy In theory, effects may occur at different degrees of target occupancy and may be
species dependent. The relationship between target occupancy and effect is
therefore important for the understanding of inter- and intraindividual
variability. Information on target occupancy is available by bioassays in vitro,
tracer displacement in postmortem tissue in vivo and noninvasive PET/SPECT
imaging.
[42,44,47,48,78–80]
Type 3 Quantification of the target site activation By means of in vitro bioassays, information can be obtained on receptor
activation in animal and man. Techniques like quantitative
electroencephalograms (EEG) and functional-magnetic resonance imaging
(fMRI) can obtain specific receptor activation data in preclinical and clinical in
vivo setting.
[51,58,81–85]
Type 4 Physiological measures Physiological measures should be measured in the integral biological system, as
they are often controlled by homeostatic feedback mechanisms. Such
measures can, for example, be on pituitary hormones that play a very
important role in communication between CNS and the periphery. Also for
physiological measurements quantitative EEG, PET scanning, and functional
MRI techniques are very useful.
[18,51,62,82,84–89]
Type 5 Disease processes Characterization of disease processes which are particularly useful in clinical
settings.
[37,85–87]
Type 6 Clinical endpoints Clinical endpoints such as occurrence of a disease, symptom, sign, or laboratory
abnormality that links to target outcomes.
[88]
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duction, and homeostatic feedback mechanisms. Such insight
is obtained by integration of data obtained from multilevel
studies, that is, measurement of different biomarker types in a
time-dependent manner [19,71,91,92,93]. In all cases, the
experimental approach should be such that a distinction can
be made between drug-specific and system-specific proper-
ties, to allow for scaling between drugs and/or scaling
between species [61].
3. Conclusion
For a proper CNS effect, the drug should have the ability to
access the CNS ‘at the right place, at the right time, and at the
right concentration.’ To develop treatments with improved
safety and efficacy, one of the scientific challenges is to under-
stand the biological mechanisms underlying the PK–PD rela-
tionships of CNS drugs. The currently applied simplistic
approach to produce data on multiple processes in isolation
is not informative as processes are context dependent and
interdependent. The knowledge on heterogeneity (variability)
in rate and extent of processes between drug dosing and CNS
effects is needed to predict the impact of drug-induced and
disease-induced perturbations in the biological system. To
that end, the integrative ‘Mastermind Research Approach’
[36] is needed to decipher the interrelationships of processes
that govern plasma PK, BBB transport, intra-brain distribution,
as well as CNS effects in different conditions.
4. Expert opinion
One of the major weaknesses in CNS drug discovery and
development has been the tendency to oversimplify relevant
factors underlying CNS disease and drug effects. Typically,
parameter values of PK, PD, and disease processes were
obtained in isolation, in different systems, thereby ignoring
their interrelationships and systems dependencies. Simple
decision trees based on such isolated parameter values were
used to drive decisions on taking compounds further in devel-
opment or not. However, this has not led to knowledge and
understanding the system, in terms of interdependencies and
condition dependent rate and extent of multiple processes
between drug dosing, neuro-PK, and neuro-PD, as needed
for predictions.
In the relationship between plasma PK and neuro-PK, a first
improvement was by the notion for the need for unbound
drug concentration-time profiles in plasma and brain to
inform on rate and extent of BBB transport, which can only
be provided by the microdialysis technique. A second
improvement was on understanding of extra-intracellular
drug distribution within the brain (at presumed steady-state
conditions), using the brain slice technique. Then, knowledge
on (steady state) distribution of bound and unbound drug
between plasma, brain ECF, brain intracellular space, and cel-
lular compartments, was integrated in the Combinatory
Mapping Approach [22]. This approach has recently been
embraced by a number of pharmaceutical companies.
A first left-over issue is, however, to understand time-depen-
dency. Even in chronic dosing, fluctuations in plasma and CNS
drug levels may occur and may have important consequences
for CNS TO [44]. Also, relationships between concentration–
time profiles in brainECF and intracellular space (drug target
sites) and between those target-site concentration–time pro-
files and the ones in CSF compartments are important, as
mostly only CSF can be obtained in the clinical setting and
should be relied on for having information about drug con-
centrations at the target site [4]. A number of CNS PBPK
models have been developed, however, only addressing
steady-state conditions [30,33]. The use of extensive series
data sets on unbound drug concentrations, obtained in paral-
lel in brainECF and different CSF locations in the rat, a generic
semi-PBPK brain rat model has been developed [34] followed
by the full-PBPK brain rat model [39]. This model can scale
between species, and allows prediction of concentration–time
profiles of compounds in multiple compartments of the
human brain on the basis of solely physicochemical properties
of compounds [39]
This indicates the following future perspective for predic-
tion of neuro PK and TO profiles: In a very early stage of drug
development, physicochemical properties of drugs can be
measured in vitro and/or predicted by in silico models. Also,
plasma PK profiles can be predicted by currently available full
PBPK models. This information on plasma PK and physico-
chemical drug properties can inform the CNS PBPK model to
predict neuro-PK of individual candidate compounds, in either
rat or human. Then, in vitro drug-target binding kinetics can
be included in the model to predict TO-time profiles in the
specific species selected. TO predictions could be validated by
actual measurements. With this approach fewer animals are
needed (replacement by using in silico models). Also, clinical
trials will be better informed, needing fewer individuals and
samples per individual for first-in human studies.
A next, important challenge is prediction of drug effects,
especially in disease states. Currently, to link (neuro-)PK to the
systems response, PK–PDmodeling is often applied. These mod-
els can include target activation (receptor theory [65–68]), signal
transduction [57–61], interspecies differences [62], tolerance and
sensitization [63], and intra- and interindividual variability. Also
here, it should be noted that parameter values of PK, PD, and
disease processes should not be obtained in isolation, and in
different systems, because in such manner interrelationships
and systems dependencies of processes cannot be assessed.
Moreover, so far, PK–PD approaches have typically focused on
a single anticipated drug effects. As a drug probably has addi-
tional, unknown effects, quantitative insights in CNS drug effects
should better be obtained for the whole biological system
(systems-wide approach), thereby including the unknown
mechanisms of action [69,70]. Here, also, time-course data,
obtained at different biomarker levels (Table 1) under multiple
conditions, is key to be able to apply mathematical modeling for
unraveling interrelationships and condition dependencies.
Where it concerns body fluids, serial sampling, and where pos-
sible microdialysis, is very useful. Such time-course samples can
be subjected to ‘omics’ approaches that will broaden our under-
standing of (changes in) the networks that compose the biolo-
gical system, in health and disease. Especially, a
pharmacometabolomics approach is suggested for potentially
multi-target neuropharmacodynamics. In addition, the use of
imaging techniques should be considered, as those can be
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applied to animals as well as human subjects, providing transla-
tional insights. Though ‘omic’ approaches are expensive, it is the
only way to go if we wish to have better insights into condition-
dependency of biological systems processes.
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